129 related articles for article (PubMed ID: 15461062)
41. Sarpogrelate hydrochloride, a selective 5-HT2A antagonist, improves vascular function in patients with peripheral arterial disease.
Miyazaki M; Higashi Y; Goto C; Chayama K; Yoshizumi M; Sanada H; Orihashi K; Sueda T
J Cardiovasc Pharmacol; 2007 Apr; 49(4):221-7. PubMed ID: 17438407
[TBL] [Abstract][Full Text] [Related]
42. PGE(1) short term therapy in critical lower limb ischemia.
Bandiera G; Forletta M; Di Paola FM; Cirielli C
Int Angiol; 2003 Mar; 22(1):58-63. PubMed ID: 12771858
[TBL] [Abstract][Full Text] [Related]
43. Iontophoretic administration of prostaglandin E1 in peripheral arterial occlusive disease.
Sakurai T; Yamamura K
Ann Pharmacother; 2003 May; 37(5):747. PubMed ID: 12708957
[No Abstract] [Full Text] [Related]
44. [Prostacyclin and pentoxifylline in the treatment of patients with inoperable occlusions of the peripheral arteries of the lower extremities].
Maksimović ZV
Srp Arh Celok Lek; 1999; 127(7-8):249-53. PubMed ID: 10624398
[TBL] [Abstract][Full Text] [Related]
45. Effects of a 4-week treatment with prostaglandin E1 on plasma endothelin-1 release in patients with intermittent claudication.
Mangiafico RA; Malatino LS; Santonocito M; Messina R; Attinà T; Dell'Arte S; Sarnataro F
Int J Clin Pharmacol Ther; 1999 Jul; 37(7):347-51. PubMed ID: 10442509
[TBL] [Abstract][Full Text] [Related]
46. Recanalization of chronic peripheral arterial occlusions by alternating intra-arterial rt-PA and PGE1.
Kröger K; Hwang I; Rudofsky G
Vasa; 1998 Feb; 27(1):20-3. PubMed ID: 9540428
[TBL] [Abstract][Full Text] [Related]
47. [Analysis of costs and results of prostaglandin (PGE1 alpha-cyclodestrin) therapy of peripheral arterial diseases].
Bucci M; Iacobitti P; Laurora G; Cesarone MR
Minerva Cardioangiol; 1998 Oct; 46(10 Suppl 1):9-15. PubMed ID: 10658439
[TBL] [Abstract][Full Text] [Related]
48. Orally active prostacyclin analogue for cardiovascular disease.
Nagaya N
Int Angiol; 2010 Apr; 29(2 Suppl):14-8. PubMed ID: 20357744
[TBL] [Abstract][Full Text] [Related]
49. Antithrombotic effects of KP-10614, a novel and stable prostacyclin (PGI2) analog.
Kanayama T; Kimura Y; Iseki K; Hayashi Y; Tamao Y; Mizogami S
J Pharmacol Exp Ther; 1990 Dec; 255(3):1210-7. PubMed ID: 1702154
[TBL] [Abstract][Full Text] [Related]
50. [Effect of intra-arterial and intravenous PGE1 infusions on transcutaneous oxygen pressure in patients with critical ischemia of the extremities].
Weiss T; Griesshaber J; Rogatti W; Kistner O; Hsu E; Jansen T; Diehm C
Vasa Suppl; 1991; 33():341-2. PubMed ID: 1788749
[TBL] [Abstract][Full Text] [Related]
51. Effects of intra-arterial prostaglandin E1 in patients with peripheral arterial occlusive disease.
Creutzig A; Creutzig H; Alexander K
Eur J Clin Invest; 1986 Dec; 16(6):480-5. PubMed ID: 3104047
[TBL] [Abstract][Full Text] [Related]
52. Inhibitory effect of prostaglandin E1 on laurate-induced peripheral vascular occlusive sequelae in rabbits: optimized topical formulation with beta-cyclodextrin derivative and penetration enhancer HPE-101.
Adachi H; Irie T; Uekama K; Manako T; Yano T; Saita M
J Pharm Pharmacol; 1992 Dec; 44(12):1033-5. PubMed ID: 1361553
[TBL] [Abstract][Full Text] [Related]
53. Potentiation of alpha-naphthyl thiourea-induced lung injury by prostaglandin E1 and platelet depletion.
Fantone JC; Kunkel RG; Kinnes DA
Lab Invest; 1984 Jun; 50(6):703-10. PubMed ID: 6233454
[TBL] [Abstract][Full Text] [Related]
54. Iontophoretic application of prostaglandin E1 for improvement in peripheral microcirculation.
Saeki S; Yamamura K; Matsushita M; Nishikimi N; Sakurai T; Nimura Y
Int J Clin Pharmacol Ther; 1998 Oct; 36(10):525-9. PubMed ID: 9799055
[TBL] [Abstract][Full Text] [Related]
55. Efficacy of continuous infusion of prostaglandin E1 through the superior mesenteric artery against ischemic liver cell necrosis after hepatic artery occlusion.
Kato T; Sato T; Kurokawa T; Nanjo H; Asanuma Y; Koyama K
Transplantation; 2003 Nov; 76(9):1340-5. PubMed ID: 14627913
[TBL] [Abstract][Full Text] [Related]
56. Formation of 13,14-dihydro-prostaglandin E1 during intravenous infusions of prostaglandin E1 in patients with peripheral arterial occlusive disease.
Peskar BA; Hesse WH; Rogatti W; Diehm C; Rudofsky G; Schweer H; Seyberth HW
Prostaglandins; 1991 Mar; 41(3):225-8. PubMed ID: 1852896
[TBL] [Abstract][Full Text] [Related]
57. Neutralization of prostaglandin E1 intravenous solution reduces infusion phlebitis.
Fujita M; Hatori N; Shimizu M; Yoshizu H; Segawa D; Kimura T; Iizuka Y; Tanaka S
Angiology; 2000 Sep; 51(9):719-23. PubMed ID: 10999612
[TBL] [Abstract][Full Text] [Related]
58. Beneficial effects of intravenous administration of lipo-prostaglandin E1 on the ischemic gastric tube in pigs.
Tobari S; Ikeda Y; Takami H
J Surg Res; 2005 Nov; 129(1):79-84. PubMed ID: 16087193
[TBL] [Abstract][Full Text] [Related]
59. Therapeutic efficacy of intravenously applied prostaglandin E1.
Scheffler P; de la Hamette D; Leipnitz G
Vasa Suppl; 1989; 28():19-25. PubMed ID: 2609240
[TBL] [Abstract][Full Text] [Related]
60. Application of lipid microspheres containing prostaglandin E1 ointment to peripheral ischemic ulcers.
Sakakibara Y; Jikuya T; Mitsui T
Dermatology; 1997; 195(3):253-7. PubMed ID: 9407173
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
